Literature DB >> 22451244

Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy.

Merja Kokki1, Pyry Välitalo, Ilpo Rasanen, Sirpa Aaltomaa, Ilkka Ojanperä, Matti Eskelinen, Hannu Kokki.   

Abstract

PURPOSE: To characterize the pharmacokinetics (PK) of oxycodone following intravenous injection and administration of three oral dosage forms (solution, capsule, and controlled-release tablet) in elderly patients (age 76-89 years) undergoing cystoscopy.
METHODS: This was an open, randomized study with two sequences and two visits in 15 elderly patients. The patients were given intravenous injection (over 10 min) of 5 mg of oxycodone hydrochloride trihydrate. Oxycodone hydrochloride (5 mg in all forms) was orally administered as a solution, a capsule, and a controlled-release tablet. Venous blood samples were collected up to 17 h after oxycodone administration. Population PK parameters were calculated with NONMEM VI 2.0. For intravenous injection we calculated clearance, volume of distribution at steady state, and the half-life of elimination, and for oral dosage forms also the absolute bioavailability.
RESULTS: Clearance of the intravenous injections was 28.9 L/h; the volume of distribution at steady state and the half-life of elimination were 186 L and 5.2 h, respectively. The absolute bioavailability of oxycodone was 59 % from oral solutions, 64 % from capsules, and 55 % from controlled-release tablets.
CONCLUSIONS: Our results indicate that, in the elderly, the bioavailability of the three different oral dosage forms of oxycodone is fairly similar.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451244     DOI: 10.1007/s00228-012-1267-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

Review 2.  Aging biology and geriatric clinical pharmacology.

Authors:  Allan J McLean; David G Le Couteur
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

Review 3.  Pharmacokinetics in older persons.

Authors:  Barry J Cusack
Journal:  Am J Geriatr Pharmacother       Date:  2004-12

4.  Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.

Authors:  Hannu Kokki; Ilpo Rasanen; Merja Lasalmi; Sanna Lehtola; Veli-Pekka Ranta; Kari Vanamo; Ilkka Ojanperä
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Pharmacokinetic dosage guidelines for elderly subjects.

Authors:  Klaus Turnheim
Journal:  Expert Opin Drug Metab Toxicol       Date:  2005-06       Impact factor: 4.481

6.  Conducting clinical research in geriatric populations.

Authors:  A W Zimmer; E Calkins; E Hadley; A M Ostfeld; J M Kaye; D Kaye
Journal:  Ann Intern Med       Date:  1985-08       Impact factor: 25.391

Review 7.  Oxycodone.

Authors:  Eija Kalso
Journal:  J Pain Symptom Manage       Date:  2005-05       Impact factor: 3.612

8.  Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.

Authors:  Gunnar H Gislason; Jeppe N Rasmussen; Steen Z Abildstrom; Tina K Schramm; Morten L Hansen; Emil L Fosbøl; Rikke Sørensen; Fredrik Folke; Pernille Buch; Niels Gadsbøll; Søren Rasmussen; Henrik E Poulsen; Lars Køber; Mette Madsen; Christian Torp-Pedersen
Journal:  Arch Intern Med       Date:  2009-01-26

Review 9.  The elderly patient and postoperative pain treatment.

Authors:  Frédéric Aubrun; Frédéric Marmion
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2007-03

10.  Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.

Authors:  Tuija H Nieminen; Nora M Hagelberg; Teijo I Saari; Antti Pertovaara; Mikko Neuvonen; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Anesthesiology       Date:  2009-06       Impact factor: 7.892

View more
  9 in total

1.  CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.

Authors:  Rajiv Balyan; Marc Mecoli; Raja Venkatasubramanian; Vidya Chidambaran; Nichole Kamos; Smokey Clay; David L Moore; Jagroop Mavi; Chris D Glover; Peter Szmuk; Alexander Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2017-02-17       Impact factor: 2.533

Review 2.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

3.  Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?

Authors:  Bruce Charles; Janet Hardy; Helen Anderson; Angela Tapuni; Rani George; Ross Norris
Journal:  Support Care Cancer       Date:  2014-02       Impact factor: 3.603

Review 4.  Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.

Authors:  Karin C Söderberg Löfdal; Marine L Andersson; Lars L Gustafsson
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

5.  Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain.

Authors:  Zhu Luo; Jia Miao; Shiqing Shu; Ying Wang; Xiaohong Zhu; Chao Hu; Yali Shen
Journal:  Clin Drug Investig       Date:  2020-02       Impact factor: 2.859

6.  Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model.

Authors:  N Marsousi; Y Daali; S Rudaz; L Almond; H Humphries; J Desmeules; C F Samer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-12-17

7.  Present-day challenges and future solutions in postoperative pain management: results from PainForum 2014.

Authors:  Kristiina Kuusniemi; Reino Pöyhiä
Journal:  J Pain Res       Date:  2016-02-03       Impact factor: 3.133

8.  Opioid-Induced Bowel Dysfunction in Patients Undergoing Spine Surgery: Comparison of Oxycodone and Oxycodone-Naloxone Treatment.

Authors:  Merja Kokki; Moona Kuronen; Toivo Naaranlahti; Timo Nyyssönen; Ira Pikkarainen; Sakari Savolainen; Hannu Kokki
Journal:  Adv Ther       Date:  2016-12-05       Impact factor: 3.845

9.  Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients - a randomized trial.

Authors:  Antti Valtola; James D Morse; Pawel Florkiewicz; Heidi Hautajärvi; Pasi Lahtinen; Tadeusz Musialowicz; Brian J Anderson; Veli-Pekka Ranta; Hannu Kokki
Journal:  J Drug Assess       Date:  2020-07-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.